For improving the CD8+ T cell antigenic specificity and cytotoxicity to tumor cells, we designed 3 DC/tumor vaccines through fusing immature DCs with three common tumor cells (HepG2, A549, and MGC-803). The gene discussed is CD8A; the disease is neoplasm.